Skip to main content
. 2022 Dec 9;2022(1):329-336. doi: 10.1182/hematology.2022000345

Figure 1.

Figure 1.

(A) PFS in Mayo Clinic patients with DLBCL-RS by prior CLL treatment status. Used with the permission of Wang et al.14 (B) PFS in patients in a case series according to the presence or absence of T53 mutation/deletion. (C) PFS of patients in a case series by clonal relationship to the underlying CLL. (B) and (C) used with the permission of Rossie et al.8 RT, Richter’s transformation.